UBS Group’s Aoxing Pharmaceutical Company Inc. AXN Stock Holding History

UBS Group’s Portfolio AXN Stock Details AXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-22,423	Closed	-$4K	–	8417
2017 Q3	$4K	Sell	22,423 -522	-2%	-$142	﹤0.01%	7363
2017 Q2	$7K	Buy	+22,945	New	+$8.3K	﹤0.01%	7013
2017 Q1	–	Sell	-25,556	Closed	-$8K	–	8303
2016 Q4	$8K	Buy	25,556 +21,081	+471%	+$8.73K	﹤0.01%	7063
2016 Q3	$3K	Sell	4,475 -5,595	-56%	-$3.76K	﹤0.01%	7357
2016 Q2	$7K	Buy	10,070 +8,573	+573%	+$5.81K	﹤0.01%	7010
2016 Q1	$1K	Sell	1,497 -30,727	-95%	-$22.7K	﹤0.01%	7517
2015 Q4	$22K	Buy	+32,224	New	+$40.5K	﹤0.01%	6683
2015 Q1	–	Sell	-22	Closed	–	–	9795
2014 Q4	$0	Buy	+22	New	+$6	﹤0.01%	9711

UBS Group's AXN Position: Q4 2017 in Review

UBS Group sold out of Aoxing Pharmaceutical Company Inc. (AXN) in Q4 2017, closing a stake of 22,423 shares — an estimated $4K sold.

UBS Group first reported a position in AXN in Q4 2014 and held it in 8 quarters. The position peaked at $22K in Q4 2015. 0 funds tracked by Wall St. Rank hold AXN as of Q4 2017.

UBS Group reported no remaining Aoxing Pharmaceutical Company Inc. position as of Q4 2017 after selling out during the quarter.
UBS Group sold 22,423 Aoxing Pharmaceutical Company Inc. shares in Q4 2017, an estimated $4K.
UBS Group first reported a position in Aoxing Pharmaceutical Company Inc. in Q4 2014 and held it in 8 quarters.
UBS Group's Aoxing Pharmaceutical Company Inc. position peaked at $22K in Q4 2015.
0 funds tracked by Wall St. Rank held Aoxing Pharmaceutical Company Inc. as of Q4 2017.

Based on UBS Group's 13F filing for Q4 2017, filed 14 Feb 2018.